Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 8/20 | 0.55 |
| ▸ | ABL1 | P00519 | 7/20 | 0.52 |
| ▸ | BCR | P11274 | 7/20 | 0.52 |
| ▸ | LCK | P06239 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5029346 | 0.93 | ABL1 (0.62) | MPLABL1BCRLCKMAPK14 | |
| SCHEMBL14301955 | 0.86 | ALDH1A1 (0.48) | ABL1BCRLCKKDRALDH1A1 | |
| SCHEMBL5023760 | 0.85 | ABL1 (0.58) | MPLABL1BCRLCKKDR | |
| SCHEMBL5023723 | 0.83 | ABL1 (0.55) | MPLABL1BCRPOLBMAPT | |
| SCHEMBL5023651 | 0.83 | POLB (0.68) | ABL1BCRLCKMAPK14KDR | |
| SCHEMBL5029449 | 0.82 | MEN1 (0.62) | ABL1BCRLCKKDRPOLB | |
| SCHEMBL5027684 | 0.82 | ABL1 (0.68) | MPLABL1BCRKDRPOLB | |
| SCHEMBL5029436 | 0.82 | GAA (0.61) | ABL1BCRLCKKDRPOLB | |
| SCHEMBL5025258 | 0.81 | ROCK1 (0.64) | MPLABL1BCRKDRPOLB | |
| SCHEMBL5029324 | 0.81 | GAA (0.57) | MPLABL1BCRKDRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039466-A1 | 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors | AB SCIENCE | 2008-02-14 | — | — | US | claimed |
| CN-1934107-A | 2- (3-substituted aryl) amino-4-aryl-thiazoles as tyrosine kinase inhibitors | AB SCIENCE (FR) | 2007-03-21 | — | — | CN | claimed |
| EP-1711497-A1 | 2-(3-SUBSTITUTED-ARYL)AMINO-4-ARYL-THIAZOLES AS TYROSINE KINASE INHIBITORS | AB Science (FR) | 2006-10-18 | — | — | EP | claimed |
| WO-2005073225-A1 | 2-(3-SUBSTITUTED-ARYL)AMINO-4-ARYL-THIAZOLES AS TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2005-08-11 | — | — | WO | claimed |
| US-20080039466-A1 | 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors | AB SCIENCE | 2008-02-14 | — | — | US | disclosed |
| US-20080039466-A1 | 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors | AB SCIENCE | 2008-02-14 | — | — | US | disclosed |
| CN-1934107-A | 2- (3-substituted aryl) amino-4-aryl-thiazoles as tyrosine kinase inhibitors | AB SCIENCE (FR) | 2007-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039466-A1 | 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors | KIT, MAP3K2, RET | MPL 450/4885ABL1 22/4885BCR 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.